Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients
| Autor: | Marieke van der Zwan, MD, Carla C. Baan, PhD, Robert B. Colvin, MD, PhD, Rex N. Smith, MD, PhD, Rebecca A. White, Dorothy Ndishabandi, Alex L. Nigg, Thierry P.P. van den Bosch, PhD, Gretchen N. de Graav, MD, PhD, Marian C. Clahsen-van Groningen, MD, PhD, Dennis A. Hesselink, MD, PhD |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Transplantation Direct, Vol 5, Iss 1, p e418 (2019) |
| Druh dokumentu: | article |
| ISSN: | 2373-8731 00000000 |
| DOI: | 10.1097/TXD.0000000000000857 |
| Popis: | Background. Belatacept-based therapy in kidney transplant recipient has been shown to increase long-term renal allograft and patient survival compared with calcineurin inhibitor–based therapy, however, with an increased risk of acute T cell-mediated rejection (aTCMR). An improved understanding of costimulation blockade-resistant rejections could lead to a more personalized approach to belatacept therapy. Here, immunomic profiles of aTCMR biopsies of patients treated with either tacrolimus or belatacept were compared. Methods. Formalin-fixed paraffin-embedded renal transplant biopsies were used for immunohistochemistry and gene expression analysis using the innovative NanoString technique. To validate NanoString, transcriptomic profiles of patients with and without biopsy-proven aTCMR were compared. Biopsies from 31 patients were studied: 14 tacrolimus-treated patients with aTCMR, 11 belatacept-treated patients with aTCMR, and 6 controls without rejection. Results. A distinct pattern was seen in biopsies with aTCMR compared to negative controls: 78 genes had a higher expression in the aTCMR group (false discovery rate P value |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|